Baricitinib combined with methylprednisolone on inflammatory factors in patients with severe pneumonia

Objective: This work aims to assess the effect of baricitinib in combination with methylprednisolone in patients with pneumonia in severe conditions and their impact on inflammation markers. Methods: From DECEMBER 2022 to AUGUST 2023, 182 patients diagnosed with severe pneumonia formed the sampling frame. These selected patients were then divided into two groups based on a random number table, with 91 patients in each group. Both groups underwent treatment under a traditional placebo. The control group received methylprednisolone, while the experimental group was treated with methylprednisolone in combination with baricitinib. They were treated similarly for seven days. The groups' peri-operative blood gas, inflammatory parameters, and drug safety were compared. Results: On the seventh day of the intervention, both the groups had improved with the blood gas parameters. Additionally, the results showed that the experimental group possessed significantly higher peripheral oxygen saturation (SpO2), partial pressure of arterial oxygen (PaO2), and oxygenation index (OI) as compared to the control group (P < 0.05). The experimental group also showed a higher level of carbon dioxide than the control group, P < 0. The experimental group had a mean partial pressure (PaCO2) lower as compared to that of the control group (P < 0). Further, the finding of the observation group, on average, had a significantly lower concentration of CRP, IL-6, and IL-10 during the seventh day compared to the control group (P<0). The result showed no statistically significant difference in the frequency of adverse reactions in the two groups when the medication was given (P > 0.05). Therefore, the utilization of baricitinib in combination with methylprednisolone can ameliorate blood gas parameters and indicate the levels of inflammatory markers in patients with severe pneumonia. Therefore, the medicine is considered safe and has the potential for wider clinical application.